Amundi Pioneer Asset Management Inc. Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Amundi Pioneer Asset Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 50.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,264,232 shares of the biopharmaceutical company’s stock after selling 3,280,243 shares during the period. Amundi Pioneer Asset Management Inc. owned 0.25% of Gilead Sciences worth $204,179,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Bank of New York Mellon Corp grew its position in shares of Gilead Sciences by 199,789.8% during the third quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of Gilead Sciences by 5,733.7% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 28,491,386 shares in the last quarter. Capital Research Global Investors grew its position in shares of Gilead Sciences by 22.5% during the third quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock valued at $5,393,502,000 after purchasing an additional 12,818,301 shares in the last quarter. BlackRock Inc. grew its position in shares of Gilead Sciences by 2.2% during the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock valued at $6,516,839,000 after purchasing an additional 2,195,948 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in shares of Gilead Sciences by 21.1% during the third quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock valued at $790,738,000 after purchasing an additional 1,786,881 shares in the last quarter. Institutional investors and hedge funds own 80.20% of the company’s stock.

NASDAQ GILD traded down $0.30 during trading on Friday, hitting $62.95. The stock had a trading volume of 11,552,923 shares, compared to its average volume of 6,643,269. The company has a market cap of $80.29 billion, a P/E ratio of 10.24, a PEG ratio of 4.19 and a beta of 1.16. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.30.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the business posted $1.78 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.23 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.63 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.00%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the transaction, the director now directly owns 57,560 shares in the company, valued at $3,691,898.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,102 shares of company stock worth $2,787,375. Corporate insiders own 0.20% of the company’s stock.

A number of research analysts recently commented on GILD shares. ValuEngine downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, February 13th. Mizuho set a $88.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, March 22nd. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, February 7th. Wells Fargo & Co lowered their price target on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, February 5th. Finally, Oppenheimer raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price target for the company in a report on Thursday, January 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $82.12.

TRADEMARK VIOLATION NOTICE: “Amundi Pioneer Asset Management Inc. Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)” was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.baseballdailydigest.com/news/2019/04/21/amundi-pioneer-asset-management-inc-reduces-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Read More: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.